Monthly Prescribing Reference

Botox Approved for Pediatric Lower Limb Spasticity

The FDA has approved Botox for the treatment of lower limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. The treatment was already approved for ...
Monthly Prescribing Reference

FDA Expands Use of Botox and Dysport for Spasticity in Pediatric Patients

The FDA has approved the expanded use of Botox® (onabotulinumtoxinA; Allergan) for the treatment of spasticity in pediatric patients aged ≥2 years, including those with lower limb spasticity caused by ...
Nasdaq

FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity

DUBLIN, March 7, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license applications ...
Nasdaq

FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy

DUBLIN, Oct. 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) ...